Skip to main content
Figure 2 | BMC Psychiatry

Figure 2

From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

Figure 2

Kaplan-Meier plot: time to median symptomatic remission from baseline in the short-term study by LDX treatment group (efficacy population, n=414). Log rank P-value: <.0001. P-value indicates overall significant effect among the treatment groups and was not specifically tested between any individual dose groups. Abbreviations: d=day; LDX=lisdexamfetamine dimesylate.

Back to article page